Short-Term Debt to Capital: Boston Scientific Corporation (BSX)

Product recall risks and regulatory barriers are putting pressure on Boston Scientific (BSX), yet the GURU.Markets terminal displays a chart of the company's short-term debt-to-equity ratio, where 0.03 serves as the current parameter value. Expansion into cardiology ensures market dominance, while high physician loyalty to the company's implants guarantees the stability of long-term procurement.

This ratio assesses the level of short-term debt load relative to the company's equity. The calculation is based on comparing liabilities with a maturity of up to one year against the net asset value, which allows for the identification of liquidity risks. Analyzing the short-term liabilities to equity chart helps detect overheating in time and avoid purchasing an asset at its peak. For Boston Scientific (BSX), this balance is critically important during the aggressive capture of market share in cardiology platforms.